PMA P200048

Device
IsoPSA Assay
Applicant
Cleveland Diagnostics, Inc.
PMA number
P200048
Product code
QRF
Decision date
2025-11-28
Classification
Immunology
Generic name
Multi-analyte test system with algorithmic analysis for detection of prostate cancer
Approval order statement
Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.

Current openFDA PMA Record#

Device
IsoPSA Assay
Applicant
Cleveland Diagnostics, Inc.
PMA number
P200048
Product code
QRF
Generic name
Multi-analyte test system with algorithmic analysis for detection of prostate cancer
Decision date
2025-11-28
Decision code
APPR
Date received
2020-12-28
Approval order statement
Approval for the IsoPSA Assay.The IsoPSA Assay is an in vitro test system that combines the results of total Prostate Specific Antigen (PSA) (Elecsys, Roche Diagnostics) and free PSA (Elecsys, Roche Diagnostics) from partitioned heparinized plasma into a single numerical index. The IsoPSA Assay is indicated for use in conjunction with other patient information to aid in detection of high-grade prostate cancer (Grade Group >= 2; Gleason score >= 7) in men >= 50 years of age, with total PSA levels >= 4.0 to =< 10.0 ng/mL for whom a biopsy is being considered by a urologist based on current standard of care, before consideration of IsoPSA Assay results.Prostatic biopsy is required for the diagnosis of cancer.